ZXBio Co., Ltd is founded in 2017 at Mogan Mountain of Hi-Tech National Industry Development Zone, Huzhou.
Our company sets up a manufacturing base for producing top grade monoclonal antibody. Through a combination of intelligent-feedback software and indexed operational control system, we aim to establish an integrated manufacturing platform optimized for antibody production. The mission of our company is to develop monoclonal antibody-based research reagents, diagnostic reagents, and therapeutics for the global medical community. This could lead to job creation, efficient delivery of novel antibody-based drugs to patients of a variety of medical illness.
ZXBio pioneers a novel business philosophy of corporate indexation. By constructing all company holdings and operational procedures into a value index, ZXBio aims to maximize its value index through day to day operation. We believe this new strategy will maximize our company's efficiency to meet market needs and grow our company's value in the fastest way.
Jason Cyster is a professor of microbiology and immunology at the University of California, San Francisco. He has been a Howard Hughes Medical Institution (HHMI) Investigator for 19 years.
Mark Ansel is a professor of microbiology and immunology at the University of California, San Francisco.
Lewis L. Lanier is a professor of microbiology and immunology at the University of California, San Francisco. He is the Chair and J. Michael Bishop, MD, Distinguished Professor of the Department of Microbiology and Immunology. He is a Member of the National Academy of Sciences.
Aoshuang Chen, Yuezhen Lou, Zhimin Tang, et al. We are highly grateful for their generous support！
ZXBio develops monoclonal antibody reagents and drugs for 5 disease areas